Focused On-demand Library for tRNA-splicing endonuclease subunit Sen34

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q9BSV6

UPID:
SEN34_HUMAN

ALTERNATIVE NAMES:
Leukocyte receptor cluster member 5; tRNA-intron endonuclease Sen34

ALTERNATIVE UPACC:
Q9BSV6; A6NNB1; B0V3J1; Q9BVT1; Q9H6H5

BACKGROUND:
tRNA-splicing endonuclease subunit Sen34, alternatively named Leukocyte receptor cluster member 5, is a key enzyme in RNA biology. It identifies and cleaves the splice sites in pre-tRNA, a critical step for intron removal and tRNA maturation. This enzyme's activity ensures the proper synthesis of proteins, pivotal for cellular function and health.

THERAPEUTIC SIGNIFICANCE:
Given its association with Pontocerebellar hypoplasia 2C, a disorder marked by brain abnormalities and movement issues, the study of tRNA-splicing endonuclease subunit Sen34 holds promise for uncovering novel therapeutic avenues. Understanding the role of this protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8306 of 8789